CN105254572A — 一种奥拉帕尼的晶型及其制备方法和应用
Assigned to BEIJING COLLAB PHARMA Co Ltd · Expires 2016-01-20 · 10y expired
What this patent protects
本发明提供了一种奥拉帕尼的晶型及其制备方法和应用,本发明提供的新晶型的奥拉帕尼,使用CuK α 辐射,以2θ角度表示的粉末X射线衍射在22.9±0.5,23.4±0.5,21.0±0.5,17.1±0.5,17.3±0.5,14.2±0.5,15.0±0.5,13.5±0.5,18.6±0.5,20.6±0.5,10.2±0.5,20.3±0.5,21.9±0.5,25.8±0.5,26.5±0.5有衍射峰,且本发明所述的晶型奥拉帕尼的粒度为D50为2.45微米,粒度较小,进而使得其作为制剂时,溶出速度快,提高了产品的药效;且本发明提供的制备方法简单,得…
USPTO Abstract
本发明提供了一种奥拉帕尼的晶型及其制备方法和应用,本发明提供的新晶型的奥拉帕尼,使用CuK α 辐射,以2θ角度表示的粉末X射线衍射在22.9±0.5,23.4±0.5,21.0±0.5,17.1±0.5,17.3±0.5,14.2±0.5,15.0±0.5,13.5±0.5,18.6±0.5,20.6±0.5,10.2±0.5,20.3±0.5,21.9±0.5,25.8±0.5,26.5±0.5有衍射峰,且本发明所述的晶型奥拉帕尼的粒度为D50为2.45微米,粒度较小,进而使得其作为制剂时,溶出速度快,提高了产品的药效;且本发明提供的制备方法简单,得到的晶型奥拉帕尼性能也稳定。
Drugs covered by this patent
- Lynparza (olaparib) · AstraZeneca
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.